1<!DOCTYPE html> 2<html > 3<head> 4 <!-- Site made with Mobirise Website Builder v5.6.5, https://mobirise.com --> 5 <meta charset="UTF-8"> 6 <meta http-equiv="X-UA-Compatible" content="IE=edge"> 7 <meta name="generator" content="Mobirise v5.6.5, mobirise.com"> 8 <meta name="twitter:card" content="summary_large_image"/> 9 <meta name="twitter:image:src" content=""> 10 <meta property="og:image" content=""> 11 <meta name="twitter:title" content="Services"> 12 <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1"> 13 <link rel="shortcut icon" href="assets/images/mbr-1.png" type="image/x-icon"> 14 <meta name="description" content=""> 15 16 17 <title>Services</title> 18 <link rel="stylesheet" href="assets/web/assets/mobirise-icons2/mobirise2.css"> 19 <link rel="stylesheet" href="assets/web/assets/mobirise-icons-bold/mobirise-icons-bold.css"> 20 <link rel="stylesheet" href="assets/bootstrap/css/bootstrap.min.css"> 21 <link rel="stylesheet" href="assets/bootstrap/css/bootstrap-grid.min.css"> 22 <link rel="stylesheet" href="assets/bootstrap/css/bootstrap-reboot.min.css"> 23 <link rel="stylesheet" href="assets/parallax/jarallax.css"> 24 <link rel="stylesheet" href="assets/web/assets/gdpr-plugin/gdpr-styles.css"> 25 <link rel="stylesheet" href="assets/animatecss/animate.css"> 26 <link rel="stylesheet" href="assets/dropdown/css/style.css"> 27 <link rel="stylesheet" href="assets/socicon/css/styles.css"> 28 <link rel="stylesheet" href="assets/theme/css/style.css"> 29 <link rel="preload" href="https://fonts.googleapis.com/css?family=Jost:100,200,300,400,500,600,700,800,900,100i,200i,300i,400i,500i,600i,700i,800i,900i&display=swap" as="style" onload="this.onload=null;this.rel='stylesheet'"> 30 <noscript><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Jost:100,200,300,400,500,600,700,800,900,100i,200i,300i,400i,500i,600i,700i,800i,900i&display=swap"></noscript> 31 <link rel="preload" as="style" href="assets/mobirise/css/mbr-additional.css"><link rel="stylesheet" href="assets/mobirise/css/mbr-additional.css" type="text/css"> 32 33 34 35 36</head> 37<body> 38 39 <section data-bs-version="5.1" class="menu cid-sZGNcUTWCJ" once="menu" id="menu1-28"> 40 41 <nav class="navbar navbar-dropdown navbar-fixed-top navbar-expand-lg"> 42 <div class="container"> 43 <div class="navbar-brand"> 44 45 <span class="navbar-caption-wrap"><a class="navbar-caption text-success text-primary display-5" href="index.html">PT-OPENSCREEN</a></span> 46 </div> 47 <button class="navbar-toggler" type="button" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbarSupportedContent" data-bs-target="#navbarSupportedContent" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"> 48 <div class="hamburger"> 49 <span></span> 50 <span></span> 51 <span></span> 52 <span></span> 53 </div> 54 </button> 55 <div class="collapse navbar-collapse" id="navbarSupportedContent"> 56 <ul class="navbar-nav nav-dropdown nav-right" data-app-modern-menu="true"><li class="nav-item"><a class="nav-link link text-black text-primary display-4" href="index.html#header1-f">Home</a></li> 57 <li class="nav-item"><a class="nav-link link text-black text-primary display-4" href="contact.html">Contact Us</a></li></ul> 58 59 60 </div> 61 </div> 62 </nav> 63 64</section> 65 66<section data-bs-version="5.1" class="header1 cid-sWR506y31c" id="header1-y"> 67 68 69 70 <div class="mbr-overlay" style="opacity: 0.6; background-color: rgb(255, 255, 255);"></div> 71 72 <div class="align-center container"> 73 <div class="row justify-content-center"> 74 <div class="col-12 col-lg-9"> 75 <h1 class="mbr-section-title mbr-fonts-style mb-3 display-2"><strong>Services</strong></h1> 76 77 <p class="mbr-text mbr-fonts-style display-7">Working with different partners institutions, PT-OPENSCREEN offers a collection of services. <br>For service or information requests, please fill the <a href="contact.html" class="text-primary">contact form</a> and your request will be relayed to a suitable partner of the network.<br> 78<br> 79<br><br></p> 80 81 </div> 82 </div> 83 </div> 84</section> 85 86<section data-bs-version="5.1" class="features1 cid-sFzyUE9AaP" id="features1-1i"> 87 88 89 90 <div class="container-fluid"> 91 <div class="row"> 92 93 </div> 94 <div class="row"> 95 <div class="card col-12 col-md-6 col-lg-3"> 96 <div class="card-wrapper"> 97 <div class="card-box align-center"> 98 <div class="iconfont-wrapper">
99 <span class="mbr-iconfont mbrib-bold"></span> 100 </div> 101 <h5 class="card-title mbr-fonts-style display-5">Biology</h5> 102 <p class="card-text mbr-fonts-style display-7">From standard assays to the development of new assays and analysis of the results</p> 103 </div> 104 </div> 105 </div> 106 <div class="card col-12 col-md-6 col-lg-3"> 107 <div class="card-wrapper"> 108 <div class="card-box align-center"> 109 <div class="iconfont-wrapper"> 110 <span class="mbr-iconfont socicon-quora socicon"></span> 111 </div> 112 <h5 class="card-title mbr-fonts-style display-5">Chemistry</h5> 113 <p class="card-text mbr-fonts-style display-7">Compound bioprofiling of small molecule libraries on the panel of cell lines and data analysis.</p> 114 </div> 115 </div> 116 </div> 117 <div class="card col-12 col-md-6 col-lg-3"> 118 <div class="card-wrapper"> 119 <div class="card-box align-center"> 120 <div class="iconfont-wrapper"> 121 <span class="mbr-iconfont mobi-mbri-contact-form mobi-mbri"></span> 122 </div> 123 <h5 class="card-title mbr-fonts-style display-5"><a href="services.html#features8-1i" class="text-primary">Consultancy & Analysis</a></h5> 124 <p class="card-text mbr-fonts-style display-7">The management and execution of projects, identification of suitable experimental approach.</p> 125 </div> 126 </div> 127 </div> 128 129 </div> 130 </div> 131</section> 132 133<section data-bs-version="5.1" class="features7 cid-sX1KQuQUK4 mbr-parallax-background" id="features8-1e"> 134 <!----> 135 136 <div class="mbr-overlay" style="opacity: 0.5; background-color: rgb(255, 255, 255);"> 137 </div> 138 <div class="container"> 139 <div class="row"> 140 <div class="title col-12"> 141 142 143 </div> 144 <div class="card col-12 col-md-6"> 145 <div class="card-wrapper"> 146 <div class="top-line"> 147 <h6 class="card-title mbr-fonts-style display-5"><strong>Assay miniaturization</strong></h6> 148 <p class="mbr-text cost mbr-fonts-style display-5"></p> 149 </div> 150 <div class="bottom-line"> 151 <p class="mbr-text mbr-fonts-style display-7"> 152 Adaptation of cell or biochemical assays to microwell plate format for screening to achieve robust and reproducible readouts with minimum intra and inter-plate variability.<br><br>CBMA, CBA-UAC, CEB-UM, CEDOC, CIEQB, CNC, CQM, ToxOmics, CIIMAR, iBiMED, BioISI, ICVS, IHMT, iMED.Ulisboa, iMM, i3S<br> 153 </p> 154 </div> 155 </div> 156 </div> 157 <div class="card col-12 col-md-6"> 158 <div class="card-wrapper"> 159 <div class="top-line"> 160 <h6 class="card-title mbr-fonts-style display-5"><strong>Compound profiling</strong></h6> 161 <p class="mbr-text cost mbr-fonts-style display-5"></p> 162 </div> 163 <div class="bottom-line"> 164 <p class="mbr-text mbr-fonts-style display-7"> 165 Original small molecules or extracts from natural sources are profiled using different cellular models, including human cells from healthy and diseased-altered tissues. Assays to collect information about viability will suggest compounds with a promising therapeutic profile for follow-up experiments.<br><br>CBMA, CBA-UAC, CEDOC, CIEQB, CNC, CQM, ToxOmics, CIIMAR, iBiMED, BioISI, ICVS, IHMT, iMED.Ulisboa, iMM, i3S<br> 166 </p> 167 </div> 168 </div> 169 </div> 170 <div class="card col-12 col-md-6"> 171 <div class="card-wrapper"> 172 <div class="top-line"> 173 <h6 class="card-title mbr-fonts-style display-5"><strong>Pilot screening</strong></h6> 174 <p class="mbr-text cost mbr-fonts-style display-5"></p> 175 </div> 176 <div class="bottom-line"> 177 <p class="mbr-text mbr-fonts-style display-7"> 178 Screening of compound libraries of up to 5000 compounds as final job or as preparation to full screening campaigns of more than 100000 compounds. Includes hit confirmation and validation and may include follow-up studies.<br><br>CBMA, CBA-UAC, CEB-UM, CEDOC, CIEQB, CNC, CQM, ToxOmics, CIIMAR, iBiMED, BioISI, ICVS, IHMT, iMED.Ulisboa, iMM, i3S<br> 179 </p> 180 </div> 181 </div> 182 </div> 183 <div class="card col-12 col-md-6"> 184 <div class="card-wrapper"> 185 <div class="top-line"> 186 <h6 class="card-title mbr-fonts-style display-5"><strong>High-Throughput screening</strong></h6> 187 <p class="mbr-text cost mbr-fonts-style display-5"></p> 188 </div> 189 <div class="bottom-line"> 190 <p class="mbr-text mbr-fonts-style display-7"> 191 Screening of compound libraries more than 100000 compounds. Includes hit confirmation and validation and may include follow-up studies.<br><br>i3S<br> 192 </p> 193 </div> 194 </div> 195 </div> 196 <div class="card col-12 col-md-6"> 197 <div class="card-wrapper"> 198 <div class="top-line"> 199 <h6 class="card-title mbr-fonts-style display-5"><strong>Target deconvolution </strong></h6> 200 <p class="mbr-text cost mbr-fonts-style display-5"></p> 201 </div> 202 <div class="bottom-line"> 203 <p class="mbr-text mbr-fonts-style display-7"> 204 Cell and/or biochemical assays are designed and performed for target deconvolution of hits resulting from phenotypical-based screenings.<br><br>CBMA, CBA-UAC, CEB-UM, CEDOC, CIEQB, CNC, CQM, ToxOmics, CIIMAR, iBiMED, BioISI, ICVS, IHMT, iMED.Ulisboa, iMM, i3S<br></p> 205 </div> 206 </div> 207 </div> 208 <div class="card col-12 col-md-6"> 209 <div class="card-wrapper"> 210 <div class="top-line"> 211 <h6 class="card-title mbr-fonts-style display-5"><strong>Drug-target interactions</strong></h6> 212 <p class="mbr-text cost mbr-fonts-style display-5"></p> 213 </div> 214 <div class="bottom-line"> 215 <p class="mbr-text mbr-fonts-style display-7">Bio-Layer Interferometry is used to perform label-free, real-time study of biomolecular interactions (drug-receptor, protein-protein interactions) for determination of binding constants and kinetics.<br><br>CEB-UM<br></p> 216 </div> 217 </div> 218 </div> 219 220 221 222 223 224 225 </div> 226 </div> 227</section> 228 229<section data-bs-version="5.1" class="features7 cid-sX1Nvmqn7I mbr-parallax-background" id="features8-1g"> 230 <!----> 231 232 <div class="mbr-overlay" style="opacity: 0.5; background-color: rgb(255, 255, 255);"> 233 </div> 234 <div class="container"> 235 <div class="row"> 236 <div class="title col-12"> 237 238 239 </div> 240 <div class="card col-12 col-md-6"> 241 <div class="card-wrapper"> 242 <div class="top-line"> 243 <h6 class="card-title mbr-fonts-style display-5"><strong>Evaluation of drug-like properties</strong></h6> 244 <p class="mbr-text cost mbr-fonts-style display-5"></p> 245 </div> 246 <div class="bottom-line"> 247 <p class="mbr-text mbr-fonts-style display-7"> 248 Evaluation of physicochemical properties (e.g. solubility, lipophilicity (LogD / LogP), pKa) that can affect biological assay results and cause incorrect structure-activity relationships. This evaluation is relevant in early drug discovery programs and necessary for ADMET studies.<br><br>CIQUP, CQM, CQUM, CQC, iMED.Ulisboa, CQE<br> 249 </p> 250 </div> 251 </div> 252 </div> 253 <div class="card col-12 col-md-6"> 254 <div class="card-wrapper"> 255 <div class="top-line"> 256 <h6 class="card-title mbr-fonts-style display-5"><strong>Hit to lead or lead optimization</strong></h6> 257 <p class="mbr-text cost mbr-fonts-style display-5"></p> 258 </div> 259 <div class="bottom-line"> 260 <p class="mbr-text mbr-fonts-style display-7"> 261 For newly identified compounds with targeted biological activity (hits), optimization performed by medicinal chemistry tools is offered in order to obtain pharmacologically viable advanced candidates possessing optimized activity/potency/selectivity profiles and/or chemical novelty.<br><br>CIQUP, CQM, CQUM, CQC, iMED.Ulisboa, CQE<br> 262 </p> 263 </div> 264 </div> 265 </div> 266 <div class="card col-12 col-md-6"> 267 <div class="card-wrapper"> 268 <div class="top-line"> 269 <h6 class="card-title mbr-fonts-style display-5"><strong>Custom synthesis</strong></h6> 270 <p class="mbr-text cost mbr-fonts-style display-7"></p> 271 </div> 272 <div class="bottom-line"> 273 <p class="mbr-text mbr-fonts-style display-7"> 274 Synthesis of different chemical tools such as building blocks, standards for pharmacological and analytical purposes, degradation products or impurities, human metabolites or prodrugs to improve pharmacokinetic properties, in small to medium sized libraries.<br><br>CIQUP, CQM, CQUM, CQC, iMED.Ulisboa, CQE<br> 275 </p> 276 </div> 277 </div> 278 </div> 279 <div class="card col-12 col-md-6"> 280 <div class="card-wrapper"> 281 <div class="top-line"> 282 <h6 class="card-title mbr-fonts-style display-5"><strong>Evaluation of drug or drug candidate stability</strong></h6> 283 <p class="mbr-text cost mbr-fonts-style display-5"></p> 284 </div> 285 <div class="bottom-line"> 286 <p class="mbr-text mbr-fonts-style display-7">The evaluation of compound storage stability (in solution or solid state) and compound metabolic
286stability (namely in plasma and in hepatocytes) can be performed using chromatographic (UHPLC/HPLC) and spectrometric (NMR/MS) tools.<br> <br>CIQUP, CQM, CQUM, CQC, iMED.Ulisboa, CQE, IMM, BioISI<br> 287 </p> 288 </div> 289 </div> 290 </div> 291 <div class="card col-12 col-md-6"> 292 <div class="card-wrapper"> 293 <div class="top-line"> 294 <h6 class="card-title mbr-fonts-style display-5"><strong>Evaluation of drug or drug candidate permeability using biomimetic membrane models </strong></h6> 295 <p class="mbr-text cost mbr-fonts-style display-7"></p> 296 </div> 297 <div class="bottom-line"> 298 <p class="mbr-text mbr-fonts-style display-7"> 299 BBB, gastro-intestinal and skin permeability prediction can be attained using non-cellular (Parallel Artificial Membrane Permeability Assay) permeability assays. If needed, permeability studies using cellular assays like Caco-2 cells, can be performed.<br><br>CIQUP, CQM, CQC, iMED.Ulisboa, CQE, IMM<br></p> 300 </div> 301 </div> 302 </div> 303 <div class="card col-12 col-md-6"> 304 <div class="card-wrapper"> 305 <div class="top-line"> 306 <h6 class="card-title mbr-fonts-style display-5"><strong>Quality control of compounds</strong></h6> 307 <p class="mbr-text cost mbr-fonts-style display-5"></p> 308 </div> 309 <div class="bottom-line"> 310 <p class="mbr-text mbr-fonts-style display-7">The consortium has the necessary equipment to perform quality control of libraries of compounds and isolation/ purification of samples. The consortium also has equipment for chemical characterization (NMR, HPLC-MS).<br><br>CIQUP, CQM, CQUM, CQC, iMED.Ulisboa, CQE, BioISI<br></p> 311 </div> 312 </div> 313 </div> 314 315 316 317 318 319 320 </div> 321 </div> 322</section> 323 324<section data-bs-version="5.1" class="features7 cid-sX1SrjFkPq mbr-parallax-background" id="features8-1h"> 325 <!----> 326 327 <div class="mbr-overlay" style="opacity: 0.5; background-color: rgb(255, 255, 255);"> 328 </div> 329 <div class="container"> 330 <div class="row"> 331 <div class="title col-12"> 332 333 334 </div> 335 <div class="card col-12 col-md-6"> 336 <div class="card-wrapper"> 337 <div class="top-line"> 338 <h6 class="card-title mbr-fonts-style display-5"><strong>Construction of chemical libraries</strong></h6> 339 <p class="mbr-text cost mbr-fonts-style display-7"></p> 340 </div> 341 <div class="bottom-line"> 342 <p class="mbr-text mbr-fonts-style display-7"> 343 Synthesis of small focused libraries for screening based on target or compound class, isolation of novel compounds from biological extracts (different chromatographic techniques) and characterization of new structures (NMR, HPLC-MS).<br><br>CIQUP, CQM, CQUM, CQC, iMED.Ulisboa, CQE, CIIMAR<br> 344 </p> 345 </div> 346 </div> 347 </div> 348 <div class="card col-12 col-md-6"> 349 <div class="card-wrapper"> 350 <div class="top-line"> 351 <h6 class="card-title mbr-fonts-style display-5"><strong>Access to compound libraries</strong></h6> 352 <p class="mbr-text cost mbr-fonts-style display-5"></p> 353 </div> 354 <div class="bottom-line"> 355 <p class="mbr-text mbr-fonts-style display-7"> 356 Chemical banking for management and storage will provide access to libraries of bioactive, target-focused or diversity-based compounds, fragments, biological extracts, to compounds produced by Portuguese chemists and, as part of the EU-OPENSCREEN, to the European Chemical Biology Library.<br><br>i3S, CBMA, CBA-UAC, CEB-UM, CEDOC, CIEQB, CNC, CQM, ToxOmics, CIIMAR, iBiMED, BioISI, ICVS, IHMT, iMED.Ulisboa, iMM<br> 357 </p> 358 </div> 359 </div> 360 </div> 361 <div class="card col-12 col-md-6"> 362 <div class="card-wrapper"> 363 <div class="top-line"> 364 <h6 class="card-title mbr-fonts-style display-5"><strong>Access to libraries of tools for genome-wide gene perturbation</strong></h6> 365 <p class="mbr-text cost mbr-fonts-style display-7"></p> 366 </div> 367 <div class="bottom-line"> 368 <p class="mbr-text mbr-fonts-style display-7"> 369 Libraries of siRNAs, microRNAs, dsRNAs (C.elegans), CRISPR (guide RNA) and yeast mutants allow the identification of disease-relevant target genes that could be further used as basis for the development of target-based chemical screens.<br><br>CNC, ICVS, BioISI, CBMA, i3S<br> 370 </p> 371 </div> 372 </div> 373 </div> 374 <div class="card col-12 col-md-6"> 375 <div class="card-wrapper"> 376 <div class="top-line"> 377 <h6 class="card-title mbr-fonts-style display-5"><strong>Access to readout instruments</strong></h6> 378 <p class="mbr-text cost mbr-fonts-style display-7"></p> 379 </div> 380 <div class="bottom-line"> 381 <p class="mbr-text mbr-fonts-style display-7"> 382 Access to microplate readers (absorbance, fluorescence, luminescence and related technologies) and automated widefield and confocal microscopes (high-content assays).<br><br>CBMA, CBA-UAC, CEB-UM, CEDOC, CIEQB, CNC, CQM, ToxOmics, CIIMAR, iBiMED, BioISI, ICVS, IHMT, iMED.Ulisboa, iMM, i3S<br> 383 </p> 384 </div> 385 </div> 386 </div> 387 <div class="card col-12 col-md-6"> 388 <div class="card-wrapper"> 389 <div class="top-line"> 390 <h6 class="card-title mbr-fonts-style display-5"><strong>Medicinal Chemistry projects and consulting</strong></h6> 391 <p class="mbr-text cost mbr-fonts-style display-7"></p> 392 </div> 393 <div class="bottom-line"> 394 <p class="mbr-text mbr-fonts-style display-7"> 395 The consortium has experience in the management and execution of projects of preclinical Medicinal Chemistry. The consortium offers both consultancy in project management and design, synthesis of dedicated libraries and characterization of new structures (NMR, HPLC-MS).<br><br>CIQUP, CQM, CQUM, CQC, iMED.Ulisboa, CQE, BioISI<br> 396 </p> 397 </div> 398 </div> 399 </div> 400 <div class="card col-12 col-md-6"> 401 <div class="card-wrapper"> 402 <div class="top-line"> 403 <h6 class="card-title mbr-fonts-style display-5"><strong>Consultancy on experimental screening strategy</strong></h6> 404 <p class="mbr-text cost mbr-fonts-style display-7"></p> 405 </div> 406 <div class="bottom-line"> 407 <p class="mbr-text mbr-fonts-style display-7"> 408 Identification of suitable experimental approach: cell or biochemical assay, chemical libraries size and composition, selection of suitable material and reagents, readout technology such as absorbance, fluorescence intensity, luminescence, high-content screening on automated fluorescence microscope.<br><br>CBMA, CBA-UAC, CEB-UM, CEDOC, CIEQB, CIQUP, CNC, CQM, CQUM, CQC, CQE, ToxOmics, CIIMAR, iBiMED, BioISI, ICVS, IHMT, iMED.Ulisboa, iMM, i3S<br> 409 </p> 410 </div> 411 </div> 412 </div> 413 414 415 416 417 418 419 </div> 420 </div> 421</section> 422 423<section data-bs-version="5.1" class="features7 cid-sX1UhaSt5X" id="features8-1i"> 424 <!----> 425 426 427 <div class="container"> 428 <div class="row"> 429 <div class="title col-12"> 430 431 432 </div> 433 <div class="card col-12 col-md-6"> 434 <div class="card-wrapper"> 435 <div class="top-line"> 436 <h6 class="card-title mbr-fonts-style display-5"><strong>Bioimage analysis</strong></h6> 437 <p class="mbr-text cost mbr-fonts-style display-5"></p> 438 </div> 439 <div class="bottom-line"> 440 <p class="mbr-text mbr-fonts-style display-7"> 441 Automated processing of microscopy images (fluorescence or transmission) using appropriate software tools and IT infrastru
441cture to extract quantitative phenotypic data in numerical form. Extraction of multi-parametric quantitative features at the single cell level for high content screening assays.<br><br>CEDOC, CNC, BioISI, ICVS, iMM, i3S, iBiMED<br> 442 </p> 443 </div> 444 </div> 445 </div> 446 <div class="card col-12 col-md-6"> 447 <div class="card-wrapper"> 448 <div class="top-line"> 449 <h6 class="card-title mbr-fonts-style display-5"><strong>Statistical data analysis</strong></h6> 450 <p class="mbr-text cost mbr-fonts-style display-5"></p> 451 </div> 452 <div class="bottom-line"> 453 <p class="mbr-text mbr-fonts-style display-7"> 454 Efficient analysis of large numerical datasets produced by spectroscopy or image-based screening using data science tools to report the phenotypic variation caused by each chemical perturbation. Will include data visualization, exploratory data analysis, quality control and normalization.<br><br>CNC, ICVS, BioISI, iMM, i3S<br> 455 </p> 456 </div> 457 </div> 458 </div> 459 460 461 462 463 464 465 466 467 468 469 </div> 470 </div> 471</section> 472 473<section data-bs-version="5.1" class="footer3 cid-sZG3RAAujz" once="footers" id="footer3-27"> 474 475 476 477 478 479 <div class="container"> 480 <div class="media-container-row align-center mbr-white"> 481 <div class="row row-links"> 482 <ul class="foot-menu"> 483 484 485 486 487 488 <li class="foot-menu-item mbr-fonts-style display-7"> 489 <a class="text-white text-primary" href="index.html#header1-f">About</a></li><li class="foot-menu-item mbr-fonts-style display-7"> 490 <a class="text-white text-primary" href="services.html">Services</a> 491 </li><li class="foot-menu-item mbr-fonts-style display-7"><a href="training.html" class="text-white">Training</a></li><li class="foot-menu-item mbr-fonts-style display-7"><a href="contact.html" class="text-white text-primary">Contact</a> Us</li><li class="foot-menu-item mbr-fonts-style display-7"><a href="privacy.html" class="text-white text-primary">Privacy Policy</a></li><li class="foot-menu-item mbr-fonts-style display-7"><a href="cookies_p.html" class="text-white text-primary">Cookies Policy</a></li></ul> 492 </div> 493 494 <div class="row row-copirayt"> 495 <p class="mbr-text mb-0 mbr-fonts-style mbr-white align-center display-7"> 496 © Copyright 2022 PT-OPENSCREEN - Mobirise Theme</p> 497 </div> 498 </div> 499 </div> 500</section><section class="display-7" style="padding: 0;align-items: center;justify-content: center;flex-wrap: wrap; align-content: center;display: flex;position: relative;height: 4rem;"><a href="https://mobiri.se/2728161" style="flex: 1 1;height: 4rem;position: absolute;width: 100%;z-index: 1;"><img alt="" style="height: 4rem;" src="data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw=="></a><p style="margin: 0;text-align: center;" class="display-7">‌</p><a style="z-index:1" href="https://mobirise.com/builder/ai-website-generator.html">AI Website Generator</a></section>
500<script src="assets/bootstrap/js/bootstrap.bundle.min.js"></script>
500
500<script src="assets/parallax/jarallax.js"></script>
500
500<script src="assets/web/assets/cookies-alert-plugin/cookies-alert-core.js"></script>
500
500<script src="assets/web/assets/cookies-alert-plugin/cookies-alert-script.js"></script>
500
500<script src="assets/smoothscroll/smooth-scroll.js"></script>
500
500<script src="assets/ytplayer/index.js"></script>
500
500<script src="assets/dropdown/js/navbar-dropdown.js"></script>
500
500<script src="assets/theme/js/script.js"></script>
500 501 502 503<input name="cookieData" type="hidden" data-cookie-customDialogSelector='null' data-cookie-colorText='#424a4d' data-cookie-colorBg='rgba(234, 239, 241, 0.88)' data-cookie-textButton='Agree' data-cookie-colorButton='' data-cookie-colorLink='#424a4d' data-cookie-underlineLink='true' data-cookie-text="We use cookies to give you the best experience. Read our <a href='cookies_p.html'>cookie policy</a>."> 504 <div id="scrollToTop" class="scrollToTop mbr-arrow-up"><a style="text-align: center;"><i class="mbr-arrow-up-icon mbr-arrow-up-icon-cm cm-icon cm-icon-smallarrow-up"></i></a></div> 505 <input name="animation" type="hidden"> 506 </body> 507</html>
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.